A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

Also called NCT07881458

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07881458
  • EU CT 2026-527230-31-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, China, Germany, Japan, Puerto Rico, Romania, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07881458. Randomized; double masking; primary purpose treatment. Start 2026-10-16 (actual); primary completion 2029-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Acronym
AMPLIFY-2
Condition
Obesity
Condition
Overweight
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
eloralintide and tirzepatide
Intervention (Drug)
Tirzepatide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07881458
Content hash
7b236ec4ac4bd3b9aa65bc1e84a8c09c33fdbf4d7d0c962520af7957756d4463